NCT02312622 2023-12-12
Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Stanford University
Phase 2 Completed
Clinical Trials
4 trialsNCT05158491 2022-01-05
Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC
JenKem Technology Co., Ltd.
Phase 1/2 Unknown
NCT01773109 2020-04-03
Etirinotecan Pegol (NKTR-102) in NSCLC
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT01876446 2020-03-17
Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
Roswell Park Cancer Institute
Phase 2 Completed